Neuroblastoma is a solid tumor of the sympathetic nervous system accounting for up to 10% of pediatric cancers and 15% of cancer-related deaths. It is a useful system for investigation of stress signal-mediated apoptosis as a tumor suppression mechanism. In this study, we present evidence that p53 mediates DNA damaging drug-induced apoptosis in IMR32 cells through the caspase-9 pathway. In summary, we define a molecular pathway for mediating DNA damaging drug-induced apoptosis in human neuroblastoma IMR32 cells and suggest that inactivation of essential components of this apoptotic pathway may confer drug resistance on neuroblastoma cells.
Get full access to this article
View all access options for this article.
References
1.
AdamsJ.M., CoryS.2007. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene, 26:1324–1337.
2.
BarakY., JuvenT., HaffnerR., OrenM.1993. mdm2 expression is induced by wild-type p53 activity. EMBO J, 12:461–468.
3.
BrodeurG.M.2003. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer, 3:203–216.
4.
BrownJ.P., PaganoM.1997. Mechanism of p53 degradation. Biochim Biophys Acta, 1332:O1–O6.
5.
CaneteA., GerrardM., RubieH., CastelV., Di CataldoA., MunzerC.et al.2009. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol, 27:1014–1019.
6.
CastresanaJ.S., BelloM.J., ReyJ.A., NebredaP., QueizanA., Garcia-MiguelP.et al.1994. No TP53 mutations in neuroblastomas detected by PCR-SSCP analysis. Genes Chrom Cancer, 10:136–138.
7.
ChoiM.S., YukD.Y., OhJ.H., JungH.Y., HanS.B., MoonD.C.et al.2008. Berberine inhibits human neuroblastoma cell growth through induction of p53-dependent apoptosis. Anticancer Res, 28:3777–3784.
8.
CraxtonA., DravesK.E., GruppiA., ClarkE.A.2005. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med, 202:1363–1374.
9.
CuiH., HuB., LiT., MaJ., AlamG., GunningW.T.et al.2007. Bmi-1 is essential for the tumorigenicity of neuroblastoma cells. Am J Pathol, 170:1370–1378.
10.
CuiH., LiT., DingH.F.2005. Linking of N-Myc to death receptor machinery in neuroblastoma cells. J Biol Chem, 280:9474–9481.
11.
CuiH., SchroeringA., DingH.F.2002. p53 mediates DNA damaging drug-induced apoptosis through a caspase-9-dependent pathway in SH-SY5Y neuroblastoma cells. Mol Cancer Ther, 1:679–686.
12.
DayT.W., WuC.H., SafaA.R.2009. Etoposide induces protein kinase Cdelta- and caspase-3-dependent apoptosis in neuroblastoma cancer cells. Mol Pharmacol, 76:632–640.
13.
EggertA., IkegakiN., LiuX.G., BrodeurG.M.2000. Prognostic and biological role of neurotrophin-receptor TrkA and TrkB in neuroblastoma. Klin Padiatr, 212:200–205.
14.
El-DeiryW.S., TokinoT., VelculescuV.E., LevyD.B., ParsonsR., TrentJ.M.et al.1993. WAF1, a potential mediator of p53 tumor suppression. Cell, 75:817–825.
15.
GoldmanS.C., ChenC.Y., LansingT.J., GilmerT.M., KastanM.B.1996. The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. Am J Pathol, 148:1381–1385.
16.
HakemR., HakemA., DuncanG.S., HendersonJ.T., WooM., SoengasM.S.et al.1998. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell, 94:339–352.
17.
HemannM.T., BricA., Teruya-FeldsteinJ., HerbstA., NilssonJ.A., Cordon-CardoC.et al.2005. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature, 436:807–811.
18.
HerrmannM., LorenzH.M., VollR., GrunkeM., WoithW., KaldenJ.R.1994. A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res, 22:5506–5507.
19.
HollsteinM., SidranskyD., VogelsteinB., HarrisC.C.1991. p53 mutations in human cancers. Science, 253:49–53.
20.
HosoiG., HaraJ., OkamuraT., OsugiY., IshiharaS., FukuzawaM.et al.1994. Low frequency of the p53 gene mutations in neuroblastoma. Cancer, 73:3087–3093.
21.
ImamuraJ., BartramC., BertholdF., HarmsD., NakamuraH., KoefflerH.1993. Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. Cancer Res, 53:4053–4058.
22.
JacobsJ.F., van BokhovenH., van LeeuwenF.N., Hulsbergen-van de KaaC.A., de VriesI.J., AdemaG.J.et al.2009. Regulation of MYCN expression in human neuroblastoma cells. BMC Cancer, 9:239.
23.
KeshelavaN., ZuoJ.J., ChenP., WaidyaratneS.N., LunaM.C., GomerC.J.et al.2001. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res, 61:6185–6193.
24.
KomuroH., HayashiY., KawamuraM., HayashiK., KanekoY., KamoshitaS.et al.1993. Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas. Cancer Res, 53:5284–5288.
KusafukaT., FukuzawaM., OueT., KomotoY., YonedaA., OkadaA.1997. Mutation analysis of p53 gene in childhood malignant solid tumors. J Pediatr Surg, 32:1175–1180.
27.
LiP., NijhawanD., BudihardjoI., SrinivasulaS.M., AhmadM., AlnemriE.S.et al.1997. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 91:479–489.
28.
LindstromM.S., KlangbyU., WimanK.G.2001. p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. Oncogene, 20:2171–2177.
29.
LiuX.S., KimC.N., YangJ., JemmersonR., WangX.D.1996. Induction of apoptotic program in cell-free extracts—requirement for dATP and cytochrome c. Cell, 86:147–157.
30.
LoweS.W., RuleyH.E., JacksT., HousmanD.E.1993a. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74:957–967.
31.
LoweS.W., SchmittE.M., SmithS.W., OsborneB.A., JacksT.1993b. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature, 362:847–849.
MeletisK., WirtaV., HedeS.M., NisterM., LundebergJ., FrisenJ.2006. p53 suppresses the self-renewal of adult neural stem cells. Development, 133:363–369.
34.
OryD., NeugeborenB., MulliganR.1996. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci U S A, 93:11400–11406.
35.
PizzoP., PoplackD.1997. Principles and Practice of Pediatric Oncolgy, 3rd. Lippincott-Raven Publishers: Philadelphia.
36.
Ricci-VitianiL., LombardiD.G., PilozziE., BiffoniM., TodaroM., PeschleC.et al.2007. Identification and expansion of human colon-cancer-initiating cells. Nature, 445:111–115.
37.
RichT., AllenR., WyllieA.2000. Defying death after DNA damage. Nature, 407:777–783.
38.
RomagnoliM., TrichetV., DavidC., ClementM., MoreauP., BatailleR.et al.2007. Significant impact of survivin on myeloma cell growth. Leukemia, 21:1070–1078.
39.
SchwabM., WestermannF., HeroB., BertholdF.2003. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol, 4:472–480.
40.
SoengasM.S., AlarconR.M., YoshidaH., GiacciaA.J., HakemR., MakT.W.et al.1999. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science, 284:156–159.
41.
SrinivasulaS.M., AhmadM., Fernandes-AlnemriT., AlnemriE.S.1998. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell, 1:949–957.
42.
TeitzT., WeiT., LiuD., ValentineV., ValentineM., GrenetJ.et al.2002. Caspase-9 and Apaf-1 are expressed and functionally active in humna neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN. Oncogene, 21:1848–1858.
43.
TeweyK., RoweT., YangL., HalliganB., LiuL.1984. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science, 226:466–468.
44.
TweddleD., MalcolmA., BownN., PearsonA., LunecJ.2001. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res, 61:8–13.
45.
VoganK., BernsteinM., LeclercJ.M., BrissonL., BrossardJ., BrodeurG.M.et al.1993. Absence of p53 gene mutations in primary neuroblastomas. Cancer Res, 53:5269–5273.
46.
VogelsteinB., LaneD., LevineA.2000. Surfing the p53 network. Nature, 408:307–310.
47.
WozniakA., RossW.1983. DNA damage as a basis for 4′-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity. Cancer Res, 43:120–124.
48.
YangL., RoweT., LiuL.1985. Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells. Cancer Res, 45:5872–5876.
49.
ZouH., HenzelW.J., LiuX., LutschgA., WangX.1997. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell, 90:405–413.
